161 related articles for article (PubMed ID: 36114412)
21. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
Shamloo BK; Chhabra P; Freedman AN; Potosky A; Malin J; Weiss Smith S
Drug Saf; 2012 Jun; 35(6):507-18. PubMed ID: 22612854
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Lung Toxicity With Lenalidomide Using the Pharmacovigilance Database.
Sato J; Eren T; Murata S; Shimizu T; Uchida M
Anticancer Res; 2022 Dec; 42(12):5917-5925. PubMed ID: 36456140
[TBL] [Abstract][Full Text] [Related]
23. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
25. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
26. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
27. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
28. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database.
Matsuoka Y; Narukawa M
Ther Innov Regul Sci; 2018 May; 52(3):339-347. PubMed ID: 29714536
[TBL] [Abstract][Full Text] [Related]
30. Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database.
Park K; Soukavong M; Kim J; Kwon KE; Jin XM; Lee J; Yang BR; Park BJ
Yonsei Med J; 2017 May; 58(3):564-569. PubMed ID: 28332362
[TBL] [Abstract][Full Text] [Related]
31. [Adverse Event Trends Associated with Over-the-counter Drugs: Data Mining of the Japanese Adverse Drug Event Report Database].
Umetsu R; Abe J; Ueda N; Kato Y; Nakayama Y; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2015; 135(8):991-1000. PubMed ID: 26234358
[TBL] [Abstract][Full Text] [Related]
32. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
33. Disproportionality Analysis of Safety Signals for a Wide Variety of Opioid-Related Adverse Events in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Omoto T; Asaka J; Sakai T; Sato F; Goto N; Kudo K
Biol Pharm Bull; 2021; 44(5):627-634. PubMed ID: 33952819
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2022; 100(7):413-418. PubMed ID: 35504255
[TBL] [Abstract][Full Text] [Related]
35. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
36. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
McNeil MM; Paradowska-Stankiewicz I; Miller ER; Marquez PL; Seshadri S; Collins LC; Cano MV
Vaccine; 2019 Oct; 37(44):6760-6767. PubMed ID: 31548014
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database.
Wichelmann TA; Abdulmujeeb S; Ehrenpreis ED
Aliment Pharmacol Ther; 2021 Nov; 54(10):1290-1297. PubMed ID: 34499740
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database.
Sato J; Uchida M; Wakabayashi H; Shimizu T
Anticancer Res; 2022 Jun; 42(6):3109-3116. PubMed ID: 35641286
[TBL] [Abstract][Full Text] [Related]
40. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
